• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Corcept Therapeutics Incorporated (Amendment)

    2/9/23 11:15:26 AM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CORT alert in real time by email
    SC 13G/A 1 tv0658-corcepttherapeuticsin.htm SCHEDULE 13G/A corcepttherapeuticsinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 7)*

    Name of issuer:  Corcept Therapeutics Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  218352102

    Date of Event Which Requires Filing of this Statement: December 30, 2022

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  218352102

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    147,393

    7.  SOLE DISPOSITIVE POWER

    10,104,947

    8.  SHARED DISPOSITIVE POWER

    240,083

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    10,345,030

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    9.61%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Corcept Therapeutics Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    149 Commonwealth Drive
    Menlo Park, CA 94025

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    218352102

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 9, 2023

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $CORT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CORT

    DatePrice TargetRatingAnalyst
    12/31/2025$30.00Peer Perform → Underperform
    Wolfe Research
    12/16/2025Neutral
    UBS
    11/18/2025Peer Perform
    Wolfe Research
    11/6/2023$29.00 → $38.00Hold → Buy
    Truist
    4/11/2023$25.00Market Perform
    SVB Securities
    4/4/2023$27.00Overweight
    Piper Sandler
    2/15/2023$35.00 → $22.00Buy → Hold
    Jefferies
    8/1/2022$30.00Buy → Hold
    Truist
    More analyst ratings

    $CORT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Overall Survival Primary Endpoint Met in Corcept's Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer

    Data demonstrate a 35 percent reduction in the risk of death Both dual primary endpoints (progression-free and overall survival) were met, without the need for biomarker selection and without increased safety burden Relacorilant's New Drug Application (NDA) is under review by the U.S. Food and Drug Administration (FDA) as a treatment for patients with platinum-resistant ovarian cancer with a Prescription Drug User Fee Act (PDUFA) target action date of July 11, 2026 Relacorilant's Marketing Authorization Application (MAA) for patients with platinum-resistant ovarian cancer is also under review by the European Medicines Agency (EMA) Corcept Therapeutics Incorporated (NASDAQ:CORT)

    1/22/26 8:00:00 AM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corcept Receives Complete Response Letter for Relacorilant as a Treatment for Patients with Hypercortisolism

    Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the U.S. Food and Drug Administration (FDA or the Agency) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism. While the FDA acknowledged that Corcept's pivotal GRACE trial met its primary endpoint and that data from the company's GRADIENT trial provided confirmatory evidence, the Agency

    12/31/25 8:00:00 AM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corcept Therapeutics Announces Third Quarter Financial Results, Oncology Development Programs and Provides Corporate Update

    Revenue of $207.6 million, compared to $182.5 million in third quarter 2024 Modified 2025 revenue guidance of $800 – $850 million Net income of $19.7 million, compared to $47.2 million in third quarter 2024 Cash and investments of $524.2 million at September 30, 2025 Oncology development programs expanded to include new studies in Earlier-stage ovarian, endometrial, cervical and pancreatic cancers, in combination with chemotherapy Broad range of solid tumors, in combination with immunotherapy Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic

    11/4/25 4:05:00 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CORT
    SEC Filings

    View All

    SEC Form 8-K filed by Corcept Therapeutics Incorporated

    8-K - CORCEPT THERAPEUTICS INC (0001088856) (Filer)

    1/22/26 8:10:37 AM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Corcept Therapeutics Incorporated

    8-K - CORCEPT THERAPEUTICS INC (0001088856) (Filer)

    12/31/25 2:51:29 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Corcept Therapeutics Incorporated

    10-Q - CORCEPT THERAPEUTICS INC (0001088856) (Filer)

    11/4/25 4:12:58 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CORT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Corcept Therapeutics downgraded by Wolfe Research with a new price target

    Wolfe Research downgraded Corcept Therapeutics from Peer Perform to Underperform and set a new price target of $30.00

    12/31/25 9:53:16 AM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UBS initiated coverage on Corcept Therapeutics

    UBS initiated coverage of Corcept Therapeutics with a rating of Neutral

    12/16/25 8:47:55 AM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wolfe Research initiated coverage on Corcept Therapeutics

    Wolfe Research initiated coverage of Corcept Therapeutics with a rating of Peer Perform

    11/18/25 8:21:50 AM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CORT
    Financials

    Live finance-specific insights

    View All

    Corcept Therapeutics Announces Third Quarter Financial Results, Oncology Development Programs and Provides Corporate Update

    Revenue of $207.6 million, compared to $182.5 million in third quarter 2024 Modified 2025 revenue guidance of $800 – $850 million Net income of $19.7 million, compared to $47.2 million in third quarter 2024 Cash and investments of $524.2 million at September 30, 2025 Oncology development programs expanded to include new studies in Earlier-stage ovarian, endometrial, cervical and pancreatic cancers, in combination with chemotherapy Broad range of solid tumors, in combination with immunotherapy Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic

    11/4/25 4:05:00 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

    Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report third quarter financial results and provide a corporate update on November 4, 2025. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number and a unique access PIN. Each access PIN will accommodate one caller. Additionally, a listen-only webcast will be available by clicking here. A replay of the call will be available on the Investors / Events tab of Corcept.com. About Corcept Therape

    10/28/25 4:05:00 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

    Revenue of $194.4 million, compared to $163.8 million in second quarter 2024 Modified 2025 revenue guidance of $850 – $900 million Net income of $35.1 million, compared to $35.5 million in second quarter 2024 Cash and investments of $515.0 million at June 30, 2025 Acquired $115.4 million of Corcept common stock in second quarter 2025 Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended June 30, 2025. Financial Results

    7/31/25 4:05:00 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CORT
    Leadership Updates

    Live Leadership Updates

    View All

    Corcept Appoints Roberto Vieira as President, Oncology

    MENLO PARK, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the appointment of Roberto Vieira as President, Oncology. He will report to Joseph K. Belanoff, MD, Corcept's Chief Executive Officer, and join the company's Executive Team. Mr. Vieira joins Corcept from Mirati Therapeutics, Inc., where he served as Senior Vice President of U.S. Commercial until earlier this month. At Mirati, Mr. Vieira built the U.S. commercial o

    1/29/24 8:00:00 AM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corcept Appoints Monica Tellado as President, Emerging Markets

    MENLO PARK, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncology, metabolism, and neurology disorders by modulating the effects of the hormone cortisol, today announced the appointment of Monica Tellado as President, Emerging Markets. She will report to Joseph K. Belanoff, MD, Corcept's Chief Executive Officer, and join the company's Executive Team. Ms. Tellado's prior role was at Heartflow, where she served as Chief Financial Officer. Before joining Heartflow, Ms. Tellado spent 19 years in ascending leadership roles at Gilead Science

    11/1/23 8:00:00 AM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corcept Therapeutics Announces Appointment of Three Senior Leaders

    MENLO PARK, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe endocrine, metabolic, oncologic and neurological disorders by modulating the effects of the hormone cortisol, today announced the appointment of three individuals to Commercial and Development leadership roles. Daniel Einhorn, MD, FACP, FACE, has joined Corcept as Vice President, Endocrine Strategy; Amiel Balagtas has joined as Vice President, Development Operations; and Lyndah Dreiling, MD, has joined as Vice President, Global Oncology Development. Dr. Einhorn will report to Sean Maduck, Presid

    4/7/22 4:05:00 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CORT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Scientific Officer Hunt Hazel exercised 150,000 shares at a strike of $3.88 and covered exercise/tax liability with 77,968 shares, increasing direct ownership by 39% to 255,437 units (SEC Form 4)

    4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)

    2/11/26 5:26:28 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Development Officer Guyer William exercised 20,000 shares at a strike of $21.65 and sold $817,334 worth of shares (20,000 units at $40.87) (SEC Form 4)

    4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)

    2/5/26 5:42:50 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Baker G Leonard Jr exercised 140,000 shares at a strike of $11.49 (SEC Form 4)

    4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)

    1/29/26 4:10:05 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CORT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Corcept Therapeutics Incorporated (Amendment)

    SC 13G/A - CORCEPT THERAPEUTICS INC (0001088856) (Subject)

    3/27/24 2:32:52 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Corcept Therapeutics Incorporated (Amendment)

    SC 13G/A - CORCEPT THERAPEUTICS INC (0001088856) (Subject)

    2/14/24 4:23:00 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Corcept Therapeutics Incorporated (Amendment)

    SC 13G/A - CORCEPT THERAPEUTICS INC (0001088856) (Subject)

    2/13/24 5:02:29 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care